From: The role of the fat mass and obesity associated gene (FTO) in breast cancer risk
 | Age < 39 | ER- | ER+ | PR- | PR+ | |
---|---|---|---|---|---|---|
 | Additive | Additive | Additive | Additive | Additive | |
rs1477196 | 5.209* (1.61-16.91) | 2.466* (1.05-5.79) | 2.437** (1.44-4.11) | 2.202* (1.05-4.64) | 2.649** (1.54-4.57) | |
rs7206790 | 3.487* (1.22-9.97) | Â | 1.81* (1.08-3.02) | Â | 1.860* (1.08-3.21) | |
rs8047395 | Â | 0.349* (0.14-0.89) | Â | Â | Â | Â |
 | Stage II | Stage III/IV | Grade I | Grade II | Grade III | |
 | Additive | Additive | Additive | Dominance | Additive | Additive |
rs1477196 | 2.368* (1.21-4.63) | 3.640* (1.63-8.14) | 2.766* (1.07-7.13) | 0.345* (0.15-0.78) | 2.405* (1.22-4.75) | 3.067* (1.49-6.31) |
rs7206790 | Â | 2.319* (1.12-4.79) | Â | Â | 1.921* (0.99-3.71) | Â |
rs8047395 | Â | Â | Â | Â | Â | 0.361* (0.16-0.78) |
 | No LN | Yes LN | Her2- | Family hx - | Family hx + | |
 | Additive | Additive | Additive | Additive | Additive | |
rs1477196 | 2.722* (1.42-5.22) | 2.318* (1.28-4.18) | 2.709** (1.60-4.58) | 3.017** (1.60-5.67) | 2.501* (1.26-4.93) | |
rs7206790 | Â | 1.868* (1.04-3.35) | Â | Â | Â | 2.449* (1.28-4.69) |